Evidence map›Paper›PMID 40013136›Full record

ArticleFrontiers in immunology2025

CD21

Peter Tobias Felixberger, Geoffroy Andrieux, Andrea Maul-Pavicic, Sigune Goldacker, Ina Harder, Sylvia Gutenberger, Jonathan J M Landry, Vladimir Benes, Till Fabian Jakob, Melanie Boerries and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Elevated IL-10 is Linked With the Expansion of T-betJournal of clinical immunology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Peter Tobias FelixbergerDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Andrea Maul-PavicicDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Sigune GoldackerDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ina HarderDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Sylvia GutenbergerDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Jonathan J M LandryGenomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
Vladimir BenesGenomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
Till Fabian JakobDepartment of Oto-Rhino-Laryngology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Lars NitschkeDivision of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany.
Reinhard Edmund VollDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Klaus Warnatz *Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Baerbel Keller *Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The posttranslational modification of cellular macromolecules by glycosylation is considered to contribute to disease pathogenesis in autoimmune and inflammatory conditions. In a subgroup of patients with common variable immunodeficiency (CVID), the occurrence of such complications is associated with an expansion of naïve-like CD21 Objective: The objective of this study was to examine the surface glycome of B cells in patients with CVID and associated immune dysregulation. Methods: We performed surface lectin staining on B cells from peripheral blood and tonsils, both Results: Unlike CD21 Conclusion: CD21

Indexed as

B-LymphocytesCommon Variable ImmunodeficiencyReceptors, Complement 3dAdultFemaleFucoseGlycosylationHumansLymphocyte ActivationMaleMiddle AgedProtein Processing, Post-TranslationalFucoseReceptors, Complement 3danti-IgM/IFNγCD21low B cellsCVIDglycomeglycosylationhyperfucosylationhypersialylationT-bet

Identifiers

PMID40013136
PMCPMC11861550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.